NextVivo Analysis: $8M Raised
What is NextVivo?
NextVivo develops therapies using immune competent human-derived organoid models. Their technology creates 3D models of healthy and diseased tissues, preserving immune cell interactions. This approach supports the development of therapies for cancer, infections, and autoimmune disorders.
Location
3160 Porter Dr, Palo Alto, California 94304, United States
Employees
1-10
Founded
2021
Funding Status
Seed
Product Features & Capabilities
- 3D organoid models of human tissues
- Immune competent human-derived models for drug testing
- Therapeutic applications for cancer, infections, and autoimmune disorders
Use Cases
Generate and test human-derived cell therapies; Develop antibody therapies against cancer; Recapitulate immune system defense mechanisms; Test therapies for autoimmune disorders; Model disease progression in human tissues
See something that needs updating? Suggest edits to this profile.